AbhishekMangaonkarMD

Hematology • Rochester, MN

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias

Assistant Professor and Senior Associate Consultant, Mayo Clinic

Join to view full profile

Dr. Mangaonkar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mangaonkar's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Summary

I am a hematology/oncology fellow at the Mayo Clinic.

Education & Training

Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Hematology and Medical Oncology, 2016 - 2019
Medical College of GeorgiaResidency, Internal Medicine, 2013 - 2016
Grant Medical CollegeClass of 2012

Certifications & Licensure

MN State Medical License 2016 - 2025
MA State Medical License 2020 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Clinical Trials

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts Start of enrollment: 2023 Feb 20
Terminated
Phase 2

Publications & Presentations

PubMed

5 citations
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes.
Evandro D. Bezerra, Terra L. Lasho, Christy Finke, Antoine N. Saliba, Michelle A. Elliott
Blood Cancer Journal. 2021-03-11
45 citations
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr, Denis Vorobyev, Terra L. Lasho, David L. Marks, Ezequiel J. Tolosa
Nature Communications. 2021-05-18
72 citations
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084...
Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, Christy Finke, Prateek Pophali
Leukemia. 2020-05-01

Journal Articles

Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring Sideroblasts
Abhishek A Mangaonkar, Kebede H Begna, Leukemia Research

Authored Content

Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring SideroblastsJuly 2018